| Stage | AMGN | % of rev | ABBV | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $10.4B | 100.00% | $17.4B | 100.00% | ABBV ×1.68 |
| Gross profit | $7.6B | 73.10% | $12.9B | 74.14% | ABBV +1.0pp |
| Operating income | $3.7B | 35.79% | $6.3B | 36.01% | ABBV +0.2pp |
| Pre-tax income | $4.7B | 45.21% | $4.8B | 27.75% | AMGN +17.5pp |
| Net income | $3.9B | 37.28% | $4.2B | 24.25% | AMGN +13.0pp |
| Stage | AMGN | ABBV | Gap · A − B |
|---|---|---|---|
| Revenue | $10.4B100.00% | $17.4B100.00% | ABBV ×1.68 |
| Gross profit | 73.10%$7.6B | 74.14%$12.9B | ABBV +1.0pp |
| Operating income | 35.79%$3.7B | 36.01%$6.3B | ABBV +0.2pp |
| Pre-tax income | 45.21%$4.7B | 27.75%$4.8B | AMGN +17.5pp |
| Net income |
| 37.28%$3.9B |
| 24.25%$4.2B |
| AMGN +13.0pp |
AMGN · CTMX 10-KMar 16 '26
“Concurrent with the entry into the Amgen Agreement, Amgen purchased 1,156,069 shares of our common stock for $20.0 million.”
ABBV · CTMX 10-KMar 16 '26
“The Varseta-M payload is a topoisomerase-1 inhibitor licensed from AbbVie (formerly ImmunoGen), tailored to have anti-tumor activity against EpCAM-expressing cancer types.”